Case Report: Optimal utilization of marginal lung allografts by considering donor–recipient PGD risk compatibility and by mitigating allograft and recipient inflammatory risk

Research output: Contribution to journalArticleAcademicpeer-review

2 Downloads (Pure)

Abstract

Reducing the risk of high-grade primary graft dysfunction (PGD) is vital to achieve acceptable short- and long-term outcomes for recipients following lung transplantation. However, the utilization of injured lung allografts, which may confer a higher risk of PGD, must be considered due to the disparity between the increasing number of patients requiring lung transplantation and the limited donor pool. We describe a case in which highly marginal lung allografts were utilized with a good post-transplant outcome. Donor–recipient PGD risk compatibility was taken into consideration. Normothermic ex vivo lung perfusion (EVLP) was utilized to functionally assess the allografts. A second cold ischemia time following EVLP was avoided by converting the EVLP mode to a hypothermic oxygenated perfusion setup from which the lungs were transplanted directly. We attempted to mitigate lung ischemia-reperfusion injury in the recipient by employing cytokine adsorption both during the EVLP and intraoperatively during the implant procedure. In this case report, we describe our hypothermic oxygenated perfusion setup on EVLP for the first time. Furthermore, we describe the utilization of cytokine adsorption in two phases of the same transplant process.

Original languageEnglish
Article number1450376
Number of pages7
JournalFrontiers in Transplantation
Volume3
DOIs
Publication statusPublished - 3 Oct 2024

Keywords

  • cytokine adsorption
  • EVLP
  • hypothermic oxygenated lung perfusion
  • lung ischemia-reperfusion injury
  • lung transplant continuum
  • lung transplantation outcome
  • primary graft dysfunction

Fingerprint

Dive into the research topics of 'Case Report: Optimal utilization of marginal lung allografts by considering donor–recipient PGD risk compatibility and by mitigating allograft and recipient inflammatory risk'. Together they form a unique fingerprint.

Cite this